Generic Name and Formulations:
Finasteride 5mg; tabs.
Merck & Co., Inc.
Indications for PROSCAR:
BPH, to improve symptoms and reduce risks of acute urinary retention and need for prostate surgery. To reduce risk of symptomatic progression of BPH, with doxazosin. Limitations of use: not for the prevention of prostate cancer.
5mg once daily. Reevaluate at 6 months, then periodically.
Not for use in children or women. Pregnant women (Cat.X) and those of childbearing potential should avoid handling crushed or broken tabs.
Increased risk of high-grade prostate cancer. Monitor prostate specific antigen (PSA) values; double PSA levels for comparison with normal ranges. Rule out prostate cancer and other urological disorders prior to treatment. Monitor for obstructive uropathy. Hepatic dysfunction.
Type II 5 alpha-reductase inhibitor.
Impotence, decreased libido or ejaculate volume, breast enlargement or tenderness, rash.
Neurology Advisor Articles
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- Significant Variations in Epilepsy Surgical Strategy, Deficit Reporting Exist
- Smoking Promotes Disease Progression in Multiple Sclerosis
- Situation Framing, Language Can Influence Decision-Making
- Thrombolysis With Tenecteplase Is as Safe as Alteplase in Stroke Mimics
- FDA: Opioid Analgesic REMS Expanded to Include Immediate-Release Products